Antibody-dependent enhancement and COVID-19: Moving toward acquittal

Clin Immunol. 2020 Aug:217:108496. doi: 10.1016/j.clim.2020.108496. Epub 2020 Jun 8.

Abstract

  1. •

    Immunoglobulins represent an effective therapeutic option for the treatment of COVID-19.

  2. •

    Experimental findings of ADE with related coronaviruses provoked theoretical concerns of enhancing antibodies with COVID-19.

  3. •

    Emerging experimental and clinical data alleviate concerns and indorse the safety of antibody-based therapies for COVID-19.

Keywords: Antiviral antibodies; COVID-19; Coronavirus; Vaccines; Viral immunity.

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral / biosynthesis
  • Antibody-Dependent Enhancement*
  • Antigen-Antibody Complex / biosynthesis*
  • Antigen-Antibody Complex / drug effects
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • COVID-19
  • COVID-19 Serotherapy
  • Coronavirus Infections / complications
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Humans
  • Immune Complex Diseases / complications
  • Immune Complex Diseases / drug therapy
  • Immune Complex Diseases / immunology*
  • Immune Complex Diseases / virology
  • Immunity, Humoral
  • Immunization, Passive / methods
  • Immunoglobulin G / biosynthesis
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • Receptors, Complement / immunology
  • Receptors, Complement / metabolism
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / complications
  • Severe Acute Respiratory Syndrome / immunology
  • Severe Acute Respiratory Syndrome / therapy*
  • Severe Acute Respiratory Syndrome / virology
  • Severity of Illness Index

Substances

  • Antibodies, Viral
  • Antigen-Antibody Complex
  • Immunoglobulin G
  • Receptors, Complement